MiPLA

Discovery

MiPLA first appeared in US Patent 2,997,470A, filed on March 5, 1956, by Richard P. Pioch and assigned to Eli Lilly and Company.^[3] The patent described synthesis procedures for "lysergic acid N-methyl N-isopropyl amide" alongside several related compounds. For nearly four decades after this disclosure, no published pharmacological study followed.

Pharmacological characterization

In 1994, Huang and colleagues in David Nichols' laboratory at Purdue University published the first and only receptor binding and behavioral characterization of MiPLA.^[1] The study established its serotonin receptor affinity and confirmed that it produced LSD-like effects in trained rats at proportionally higher doses. No further pharmacological research has been published.

Market emergence

MiPLA appeared on novel psychoactive substance markets around 2018–2019. Tanaka and colleagues documented it in paper sheet products seized in Japan, representing the first forensic identification.^[4] Brandt and colleagues subsequently analyzed blotters containing approximately 180–186 µg per unit and developed analytical methods to differentiate MiPLA from LSD.^[2] By 2023, a prodrug variant — 1cP-MiPLA — had appeared on Japanese markets,^[7] and European drug-checking proficiency tests identified MiPLA/LSD confusion as among the most common analytical errors.^[5]

Structural class

MiPLA belongs to the lysergamide family — derivatives of lysergic acid, a tetracyclic ring system containing a fused indole and quinoline skeleton. The defining structural feature is an amide linkage at the C9 position of lysergic acid, where MiPLA bears an N-methyl and N-isopropyl substituent. LSD carries two ethyl groups at the same position.^[8]

Both compounds share four total carbons across the amide alkyl groups (C1 + C3 for MiPLA versus C2 + C2 for LSD), making them positional isomers with the same molecular formula and weight but different carbon distribution.^[2]

Molecular properties

The ergoline core comprises four fused rings — an indole (A/B rings), a cyclohexene (C ring), and a piperidine (D ring) — with an N-methyl group on the basic nitrogen of the D ring.^[9]

Stereochemistry

MiPLA has two chirality centres at C6a and C9, with the pharmacologically active configuration being (6aR,9R) — identical to natural d-lysergic acid and d-LSD. Monte and colleagues confirmed that (R)-configured lysergamides are consistently more potent at serotonin receptor sites, while the (S)-epimers show dramatically reduced or absent activity.^[10]

Structure-activity relationships

Optimal LSD-like activity at 5-HT₂A requires two similarly sized alkyl groups on the amide nitrogen; increasing asymmetry or steric bulk generally reduces potency.^[8] MiPLA preserves LSD's total carbon count but introduces asymmetry — the isopropyl group is bulkier than either of LSD's ethyl groups and may adopt different orientations within the receptor binding pocket.

Molecular modeling suggests MiPLA can achieve low-energy conformations similar to LSD, indicating sufficient conformational flexibility for receptor activation despite the structural change.^[1] The most potent known lysergamide is a conformationally constrained azetidine derivative that maps the precise binding pose of LSD's diethylamide moiety within the receptor.^[11]

Mechanism of action

MiPLA acts as a serotonin 5-HT₂A receptor agonist. The only substance-specific pharmacological data come from Huang and colleagues,^[1] who demonstrated that MiPLA fully substitutes for LSD in rats trained to discriminate LSD from saline, with a dose requirement approximately 2–3× higher than LSD. This confirms that MiPLA produces qualitatively identical interoceptive effects at proportionally greater doses.

Receptor binding data show affinity at both 5-HT₂A and 5-HT₁A sites comparable to LSD. Binding at ketanserin-labeled serotonin sites was 4–5× weaker than LSD — a discrepancy that may reflect differential affinity across receptor subtypes.^[1]

By class inference from LSD pharmacology, MiPLA is expected to interact with dopamine D₁ and D₂ receptors^[12][13] and TAAR1 (TAAR₁).^[14] No substance-specific data for these targets have been published.

Pharmacokinetics

No human pharmacokinetic data exist for MiPLA. Absorption rate, peak plasma concentration time, half-life, and metabolic pathways are uncharacterized.

Community reports describe onset at 15–40 minutes orally and a total duration of 4–6 hours — substantially shorter than LSD's 8–12-hour arc.^[15][16] The shorter duration may reflect lower receptor affinity or faster dissociation from the binding site, but no study has confirmed this.

By class inference from other novel lysergamides, metabolism is presumed hepatic.^[17] Specific enzyme involvement and metabolites have not been identified.

Where it acts

No neuroimaging or electrophysiology studies have been conducted with MiPLA. As a serotonin 2A receptor agonist that fully substitutes for LSD in behavioral assays,^[1] it is expected to engage the same neural systems: disruption of default mode network coherence (associated with altered self-referential processing), increased sensory throughput through impaired thalamic gating, and elevated global functional connectivity — a state of heightened neural entropy and reduced hierarchical brain organization.

Why it matters

The REBUS model (Relaxed Beliefs Under Psychedelics) proposes that 5-HT₂A agonists reduce the brain's confidence in its existing predictions, allowing raw sensory information to propagate more freely. MiPLA's reported profile — retained perceptual effects with less cognitive disruption — could represent partial engagement of this mechanism: enough activation to alter sensory processing without fully destabilizing higher-order belief structures.

Classical psychedelics also promote structural brain changes (dendritic growth, new synaptic connections) through downstream signaling pathways. Whether MiPLA's shorter duration produces equivalent neuroplastic effects is unknown.

Toxicity

No lethal dose has been determined for MiPLA in any species, and no human fatalities or overdose case reports have been published. By class inference from LSD — which has an extremely high therapeutic index, with no confirmed human fatalities from pharmacological toxicity alone — MiPLA is expected to have low acute toxicity at typical doses. This inference has no substance-specific verification.

Psychological risks

No controlled studies of MiPLA's psychological risk profile exist. Risks are inferred from the lysergamide class:

• Acute distress: anxiety, panic, paranoia, and thought loops can occur with any serotonergic psychedelic, particularly in uncontrolled settings or at unexpectedly high doses.

• Hallucinogen persisting perception disorder (HPPD): Persistent visual disturbances following psychedelic use are documented for LSD-class compounds, with risk present even after a single exposure.^[19][20] No MiPLA-specific cases have been reported. Flashback phenomena have been documented in controlled LSD studies.^[21]

• Psychosis: serotonergic psychedelics can trigger persistent psychotic episodes in individuals with a predisposition to psychotic disorders. No MiPLA-specific data exist.

Tolerance and dependence

MiPLA produces rapid tolerance through the standard psychedelic mechanism: 5-HT₂A downregulation in frontal cortex after agonist exposure. De la Fuente Revenga and colleagues demonstrated in mice that tolerance is observable after a single dose, with progressive receptor reduction upon repeated administration.^[6]

Community-reported tolerance parameters: rapid onset within hours, half-life of approximately 6 days, full reset at approximately 14 days.^[16] Cross-tolerance exists with other serotonergic psychedelics. The rapid tolerance makes repeated daily use self-limiting.

Classical serotonergic psychedelics produce no physical dependence, no withdrawal, and are not reinforcing in animal self-administration studies. No MiPLA-specific abuse liability assessment has been conducted.

Drug interactions

Monoamine oxidase inhibitors (MAOIs): MAOIs prevent serotonin breakdown, severely amplifying the effects of any serotonergic agonist. The combination creates severe serotonin syndrome risk.^[22] This interaction is dangerous.

SSRIs/SNRIs: Chronic SSRI or SNRI use typically reduces psychedelic effects through receptor adaptation. The acute serotonin augmentation from combining a direct agonist with a reuptake inhibitor carries theoretical serotonin syndrome risk, though clinical significance is less established than for MAOI combinations.

Contraindications

No substance-specific contraindication data exist. By class pharmacology of serotonergic psychedelics:

• Psychotic disorders (absolute): Personal or first-degree family history of schizophrenia or other psychotic disorders.
• Bipolar disorder (absolute): Risk of manic episode precipitation.
• Lithium (absolute): Documented risk of seizures and severe adverse reactions when combined with serotonergic psychedelics.safety citation needed
• Heart conditions (relative): stimulant-like effects (increased heart rate, elevated blood pressure) may worsen pre-existing conditions.
• Seizure disorders (relative): seizure threshold reduction is a class risk, though substance-specific evidence for MiPLA is absent.
• Pregnancy (absolute): No reproductive toxicology data; ergoline compounds are contraindicated in pregnancy due to uterine-stimulating properties of the class.

MiPLA occupies an ambiguous legal position in most jurisdictions. It is not explicitly named in controlled substance schedules of the majority of countries but may be captured by structural analog legislation or blanket psychoactive substance bans. Its structural isomerism with LSD — sharing the identical molecular formula and weight — makes analogue act applicability particularly direct.

Analogue act considerations

MiPLA's status under the US Federal Analogue Act is particularly notable. The Act applies to substances "substantially similar" in chemical structure or pharmacological effect to a Schedule I or II substance, when intended for human consumption. MiPLA satisfies both criteria: it is a structural isomer of LSD with demonstrated LSD-like pharmacological activity.^[1] The Act requires case-by-case judicial determination, and no prosecution specifically involving MiPLA has been reported.